~ Collaboration aims to improve kidney
transplantation and enhance health equity ~
NEW
YORK, Nov. 16, 2023 /PRNewswire/ -- The National
Kidney Foundation (NKF) is proud to announce its latest investment
through the NKF Innovation Fund. ZeitLife™ Transplant Innovations,
Inc., is a global medical device company specializing in advancing
technologies to modernize kidney preservation and logistics.
"We are thrilled to invest in ZeitLife's
quest to modernize kidney preservation," said Kevin Longino, NKF CEO.
Led by industry veterans deeply committed to the organ
procurement and transplantation community, ZeitLife brings
specialized engineering, industrial design, clinical insights,
scaled manufacturing, and commercial expertise to address the most
pressing challenges and the most ambitious promises in kidney
transplantation. The company is at the forefront of advancing
preservation fluid and machine perfusion technologies, with a
relentless focus on the urgent challenges in organ transportation
and logistics. Their specialized expertise and commitment to serial
entrepreneurship in the field position them to drive the sharing of
organs over longer distances, ensuring universal compliance with
solidly established clinical evidence.
By introducing efficient new business models and routine
workflows, ZeitLife is accelerating the modernization of the
procurement and transplant system. This strategic investment with
NKF's Innovation Fund will further empower ZeitLife in their
mission to serve as a key player in the promising future of
supplying organs on demand.
"We're honored to have NKF's support and encouragement,"
said Ron Mills, CEO of ZeitLife.
"Nobody knows more about the tough challenges our customers face
and the bold innovations our company offers."
This collaboration signifies the NKF's ongoing commitment to
investing in innovative solutions that will improve the lives of
kidney disease patients and advance kidney health. The NKF's
Innovation Fund has a track record of supporting groundbreaking
companies, including Klinrisk, and Diatiro, to enhance health
equity through cutting-edge technology.
"We are thrilled to invest in ZeitLife's quest to modernize
kidney preservation and logistics," said Kevin Longino, CEO of the National Kidney
Foundation and a kidney transplant recipient. "ZeitLife's
dedication to advancing technologies and their commitment to the
betterment of kidney transplantation align perfectly with NKF's
core values. With the support of the Innovation Fund, we look
forward to accelerating the transformation of kidney preservation
and logistics, ultimately improving the lives of countless patients
waiting for kidney transplants."
Launched in 2021, the NKF Innovation Fund works to accelerate
funding, development, and commercialization of therapies that
kidney patients need and deserve. The fund invests in early to
mid-stage companies that are developing innovative, patient-centric
kidney therapies. The long-term goals of the NKF Innovation fund
are to prevent kidney disease, eliminate the transplant wait list,
and provide better, safer treatments for dialysis patients so they
can live fuller and more productive lives. For more information
about the NKF Innovation Fund, please visit
kidney.org/innovationfund.
To learn more about kidney disease and how to maintain
optimal kidney health, visit www.kidney.org/.
About Kidney Disease
In the
United States, 37 million adults are estimated to have
kidney disease, also known as chronic kidney disease—and
approximately 90 percent don't know they have it. About 1 in 3
American adults are at risk for chronic kidney disease. Risk
factors for kidney disease include: diabetes, high blood pressure,
heart disease, obesity, and family history. People of African
American, Hispanic, American Indian, Asian, or Pacific Islander
descent are at increased risk for developing the
disease. African Americans are almost 4 times more likely than
White Americans to have kidney failure. Hispanics experience kidney
failure at about double the rate of White people.
About the National Kidney Foundation
The National Kidney Foundation is revolutionizing the fight to save
lives by eliminating preventable kidney disease, accelerating
innovation for the dignity of the patient experience, and
dismantling structural inequities in kidney care, dialysis, and
transplantation. For more information about NKF,
visit www.kidney.org.
About ZeitLife
ZeitLife Transplant Innovations, Inc., is a global medical device
company advancing technologies to modernize kidney preservation and
logistics. Founded in collaboration with Fresenius Medical Care and
Mayo Clinic, and led by industry veterans in service to the organ
procurement and transplantation community, ZeitLife brings unique
clinical insights, specialized engineering, industrial design,
scaled manufacturing, and relevant commercial experience to address
today's toughest challenges and tomorrow's boldest promises.
Facebook.com
twitter.com/nkf
www.kidney.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nkfs-innovation-fund-invests-in-zeitlife-to-modernize-kidney-preservation-and-logistics-301991029.html
SOURCE The National Kidney Foundation